This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Poulaki, V. Articles by Mitsiades, N. Search for Related Content PubMed PubMed Citation Articles by Poulaki, V. Articles by Mitsiades, N.

Regulation of Vascular Endothelial Growth Factor Expression by Insulin-Like Growth Factor I in Thyroid Carcinomas

Angiogenesis Laboratory (V.P.), Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts 02114; Department of Medical Oncology (C.S.M., C.M., D.S., G.F., N.M.), Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115; Department of Pathology (V.K.), School of Medicine, Aristotle University of Thessaloniki, Thessaloniki 54621, Greece; and Endocrine Unit (S.T.-B., D.A.K., N.M.), Evgenidion Hospital, Athens 11527, Greece

Address all correspondence and requests for reprints to: Nicholas Mitsiades, M.D., Ph.D., Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Mayer Building, M555, Boston, Massachusetts 02115. E-mail: mitsiades{at}netscape.net.

Vascular endothelial growth factor (VEGF) produced by tumor cells potently stimulates endothelial cell proliferation and angiogenesis and plays a key role in the pathophysiology of several neoplasias. Hypoxia activates the VEGF promoter via response elements that bind the transcription factors hypoxia-inducible factor-1 (HIF-1) and activator protein-1 (AP-1). Yet, the paracrine signaling pathways regulating VEGF production and angiogenesis in thyroid cancer have not been fully elucidated. In this study, we, therefore, investigated the regulation of VEGF production by the thyroid carcinoma cell line SW579. We found that IGF-I up-regulated VEGF mRNA expression and protein secretion. Furthermore, transfection of SW579 cells with vector expressing a constitutively active form of Akt, a major mediator of IGF-I signaling, also stimulated VEGF expression. The IGF-I-induced up-regulation of VEGF production was associated with activation of AP-1 and HIF-1 and was abrogated by phosphatidylinositol 3-kinase inhibitors (wortmannin and LY294002); Jun kinase inhibitor (SP600125); HIF-1 antisense oligonucleotide; or geldanamycin, an inhibitor of the heat shock protein 90 molecular chaperone, which regulates the three-dimensional conformation and function of IGF-I-receptor and Akt. These data indicate that IGF-I stimulates VEGF synthesis in thyroid carcinomas in an Akt-dependent pathway via AP-1 and HIF-1 and provide the framework for clinical use of small-molecule inhibitors, including geldanamycin analogs, to abrogate proangiogenic cascades in thyroid cancer.

This work was supported by the Propondis Foundation.

Abbreviations: AP-1, Activator protein-1; FCS, fetal calf serum; HIF-1, hypoxia-inducible factor-1; Hsp, heat shock protein; IGF-IR, IGF-I receptor; JNK, Jun kinase; PE, phycoerythrin; PI-3K, phosphatidylinositol 3-kinase; VEGF, vascular endothelial growth factor.

This article has been cited by other articles:

				W. H. Lee, Y. W. Kim, J. H. Choi, S. C. Brooks III, M.-O. Lee, and S. G. Kim Oltipraz and dithiolethione congeners inhibit hypoxia-inducible factor-1{alpha} activity through p70 ribosomal S6 kinase-1 inhibition and H2O2-scavenging effect Mol. Cancer Ther., October 1, 2009; 8(10): 2791 - 2802. [Abstract] [Full Text] [PDF]

				S. Emani, B. Ramlawi, N. R. Sodha, J. Li, C. Bianchi, and F. W. Sellke Increased vascular permeability after cardiopulmonary bypass in patients with diabetes is associated with increased expression of vascular endothelial growth factor and hepatocyte growth factor J. Thorac. Cardiovasc. Surg., July 1, 2009; 138(1): 185 - 191. [Abstract] [Full Text] [PDF]

				S. Balthasar, N. Bergelin, C. Lof, M. Vainio, S. Andersson, and K. Tornquist Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells Endocr. Relat. Cancer, June 1, 2008; 15(2): 521 - 534. [Abstract] [Full Text] [PDF]

				G. Randi, M. Ferraroni, R. Talamini, W. Garavello, S. Deandrea, A. Decarli, S. Franceschi, and C. La Vecchia Glycemic index, glycemic load and thyroid cancer risk Ann. Onc., February 1, 2008; 19(2): 380 - 383. [Abstract] [Full Text] [PDF]

				E. K. Rowinsky, H. Youssoufian, J. R. Tonra, P. Solomon, D. Burtrum, and D. L. Ludwig IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor Clin. Cancer Res., September 15, 2007; 13(18): 5549s - 5555s. [Abstract] [Full Text] [PDF]

				D. Nahari, R. Satchi-Fainaro, M. Chen, I. Mitchell, L. B. Task, Z. Liu, J. Kihneman, A. B. Carroll, L. S. Terada, and F. E. Nwariaku Tumor cytotoxicity and endothelial Rac inhibition induced by TNP-470 in anaplastic thyroid cancer Mol. Cancer Ther., April 1, 2007; 6(4): 1329 - 1337. [Abstract] [Full Text] [PDF]

				Z. Wang, G. Chakravarty, S. Kim, Y. D. Yazici, M. N. Younes, S. A. Jasser, A. A. Santillan, C. D. Bucana, A. K. El-Naggar, and J. N. Myers Growth-Inhibitory Effects of Human Anti-Insulin-Like Growth Factor-I Receptor Antibody (A12) in an Orthotopic Nude Mouse Model of Anaplastic Thyroid Carcinoma Clin. Cancer Res., August 1, 2006; 12(15): 4755 - 4765. [Abstract] [Full Text] [PDF]

				C. S. Mitsiades, N. S. Mitsiades, C. J. McMullan, V. Poulaki, A. L. Kung, F. E. Davies, G. Morgan, M. Akiyama, R. Shringarpure, N. C. Munshi, et al. Antimyeloma activity of heat shock protein-90 inhibition Blood, February 1, 2006; 107(3): 1092 - 1100. [Abstract] [Full Text] [PDF]

				S.-H. Oh, W.-Y. Kim, J.-H. Kim, M. N. Younes, A. K. El-Naggar, J. N. Myers, M. Kies, P. Cohen, F. Khuri, W. K. Hong, et al. Identification of Insulin-Like Growth Factor Binding Protein-3 as a Farnesyl Transferase Inhibitor SCH66336-Induced Negative Regulator of Angiogenesis in Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., January 15, 2006; 12(2): 653 - 661. [Abstract] [Full Text] [PDF]

				M. Bjorndahl, R. Cao, L. J. Nissen, S. Clasper, L. A. Johnson, Y. Xue, Z. Zhou, D. Jackson, A. Jon Hansen, and Y. Cao Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo PNAS, October 25, 2005; 102(43): 15593 - 15598. [Abstract] [Full Text] [PDF]

				M. N. Younes, O. G. Yigitbasi, Y. W. Park, S.-J. Kim, S. A. Jasser, V. S. Hawthorne, Y. D. Yazici, M. Mandal, B. N. Bekele, C. D. Bucana, et al. Antivascular Therapy of Human Follicular Thyroid Cancer Experimental Bone Metastasis by Blockade of Epidermal Growth Factor Receptor and Vascular Growth Factor Receptor Phosphorylation Cancer Res., June 1, 2005; 65(11): 4716 - 4727. [Abstract] [Full Text] [PDF]

				J. Wu, S. Brandt, and S. M. Hyder Ligand- and Cell-Specific Effects of Signal Transduction Pathway Inhibitors on Progestin-Induced Vascular Endothelial Growth Factor Levels in Human Breast Cancer Cells Mol. Endocrinol., February 1, 2005; 19(2): 312 - 326. [Abstract] [Full Text] [PDF]

				K. M. Comerford, E. P. Cummins, and C. T. Taylor c-Jun NH2-Terminal Kinase Activation Contributes to Hypoxia-Inducible Factor 1{alpha}-Dependent P-Glycoprotein Expression in Hypoxia Cancer Res., December 15, 2004; 64(24): 9057 - 9061. [Abstract] [Full Text] [PDF]